The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients ...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with “Good-Risk” DCIS Who Forgo Radiation
When adjusting for lesion size and grade, tamoxifen after surgery decreased the risk of recurrence in the same breast.
There was no significant difference in 10-year overall survival between women who received radiation after surgery and those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback